Search
for
Sort by
Research
390-420 / 1000+ resultsresearch HIV/AIDS and Dermatological Findings at A Glance: What Has Changedin the ART Era
research Alopecia universalis. Partial response to tofacitinib
Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
research A new era for alopecia areata: New treatments and improved knowledge of the condition
Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
research Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research Consensus Document on the Clinical Management of Alopecia Areata: Recommendations from the Spanish Hair Research Group of the Spanish Academy of Dermatology and Venerology)
JAK inhibitors are recommended for severe alopecia areata if corticosteroids fail.
research Announcements
Various dermatology events and meetings were announced for 1998.
research Tofacitinib for the treatment of alopecia areata and variants in adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research Ichthyosis and Trichothiodystrophy: the Tay and PIBI(D)S Syndromes
Tay syndrome is a unique genetic disorder causing skin, hair, and developmental issues.
research ANTINOCICEPTIVE ACTIVITY OF ADIANTUM CAPILLUS IN EXPERIMENTAL ANIMALS
Adiantum capillus extract reduces pain and swelling in animals.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research A comparative study of fractional CO2 laser with topical triamcinolone acetonide versus intralesional triamcinolone acetonide in the treatment of alopecia areata
Fractional CO2 laser with topical triamcinolone is more effective and safer for treating alopecia areata than intralesional triamcinolone.
research Tinea genitalis: a new entity of sexually transmitted infection? Case series and review of the literature
Sexual activity can spread T. interdigitale, needing quick antifungal treatment to avoid permanent scarring.
research Adalimumab improves health-related quality of life (HRQoL) in patients with moderate to severe hidradenitis suppurativa (HS): Results from the first 12 weeks of PIONEER II
Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.
research 516 Possible role of ILC1 in the pathogenesis of alopecia areata (AA)
ILC1 cells contribute to hair loss in alopecia areata.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research Intestinal Lymphatic Biology, Drug Delivery, and Therapeutics: Current Status and Future Directions
The intestinal lymphatic system is active and promising for targeted drug delivery and therapies.
research Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
research 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction
Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
research SZTUCZNA INTELIGENCJA (AI). CZY TO JUŻ ŚWIT DLA SMART BEAUTY I SMART DERMATOLOGY?
AI is advancing in dermatology and cosmetology, raising questions about its potential and trustworthiness.
research Treatment of moderate-to-severe alopecia areata in patients over the age of 65 with baricitinib
Baricitinib helps treat severe hair loss in people over 65.
research AI03 Steps towards safely deploying the world’s first autonomous artificial intelligence as a medical device for skin cancer into a National Health Service teledermatology pathway
An AI device for skin cancer was successfully integrated into the NHS, improving diagnosis accuracy and service capacity.
research Alopecia universalis successfully treated with tofacitinib
Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
research Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
JAK inhibitors are effective and safe for treating severe alopecia areata.
research Multidisciplinary screening and diagnosis of obesity related diseases: an Arabic Association for the Study of Diabetes and metabolism position statement (AASD)
BMI is a simple, cost-effective tool for screening obesity and related diseases.
research LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research Laser-Assisted Drug Delivery: A Systematic Review of Safety and Adverse Events
Laser-assisted drug delivery is generally safe with mostly mild side effects.
research Highlights from the Field of Pediatric Dermatology Research from the 2023 PeDRA Annual Conference
The conference highlighted new treatments and research in pediatric skin conditions, emphasizing collaboration and innovation.
research Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG)*
Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.